摘要
目的:探讨维得利珠单抗联合美沙拉秦对中重度溃疡性结肠炎患者肠道菌群及炎症因子的影响。方法:回顾性分析赣南医学院第一附属医院2021年6月—2022年6月72例中重度溃疡性结肠炎患者的临床资料,按照治疗方法分为美沙拉秦组(n=34)和联合用药组(n=38),美沙拉秦组给予美沙拉秦,联合用药组在美沙拉秦组的基础上加用维得利珠单抗。比较两组临床疗效、肠道菌群、炎症因子及氧化应激水平。结果:联合用药组总有效率(92.11%)高于美沙拉秦组(70.59%),差异有统计学意义(P<0.05)。治疗前,两组各肠道菌群指标、炎症因子及氧化应激水平比较,差异均无统计学意义(P>0.05)。治疗后,两组乳酸杆菌、双歧杆菌较治疗前均升高,且联合用药组的乳酸杆菌、双歧杆菌均高于美沙拉秦组,两组肠球菌较治疗前均降低,且联合用药组的肠球菌低于美沙拉秦组,差异均有统计学意义(P<0.05)。治疗后,两组各炎症因子较治疗前均降低,且治疗后联合用药组的肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)均低于美沙拉秦组,差异均有统计学意义(P<0.05)。治疗后,两者氧化应激水平较治疗前均有所改善,且治疗后联合用药组的超氧化物歧化酶(SOD)高于美沙拉秦组,丙二醛及过氧化脂质(LPO)均低于美沙拉秦组,差异均有统计学意义(P<0.05)。结论:维得利珠单抗联合美沙拉秦可以有效治疗中重度溃疡性结肠炎患者,显著改善肠道菌群,减轻氧化应激和炎症反应。
Objective:To investigate the effects of Vedilizumab combined with Mesalazine on intestinal flora and inflammatory factors in patients with moderate to severe ulcerative colitis.Method:Clinical data of 72 patients with moderate to severe ulcerative colitis in the First Affiliated Hospital of Gannan Medical University from June 2021 to June 2022 were retrospectively analyzed.According to the treatment methods,they were divided into Mesalazine group(34 cases)and combination group(38 cases).The Mesalazine group was given Mesalazine,and the combination group was given Vedilizumab on the basis of the Mesalazine group.The clinical efficacy,intestinal flora,inflammatory factors and oxidative stress levels were compared between the two groups.Result:The total effective rate of the combination group(92.11%)was higher than that of the Mesalazine group(70.59%),the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in intestinal flora indexes,inflammatory factors and oxidative stress levels between the two groups(P>0.05).After treatment,the lactobacillus and bifidobacterium in both groups were higher than those before treatment,and the lactobacillus and bifidobacterium in the combination group were higher than those in the Mesalazine group,the enterococcus in both groups were decreased than those before treatment,and the enterococcus in the combination group was lower than that in the Mesalazine group,the differences were statistically significant(P<0.05).After treatment,the inflammatory factors of the two groups were decreased,and the levels of TNF-α,IL-8 and hs-CRP in the combination group were lower than those in the Mesalazine group(P<0.05).After treatment,the levels of oxidative stress in both groups were improved,and the SOD in the combination group was higher than that in the Mesalazine group,and the malondialdehyde and LPO were lower than those in the Mesalazine group,the differences were statistically significant(P<0.05).Conclusion:Vedilizumab combined with Mesalazine can effectively treat patients with moderate to severe ulcerative colitis,significantly improve intestinal flora,reduce oxidative stress and inflammatory reaction.
作者
邹玲婷
范琳
孟凡
ZOU Lingting;FAN Lin;MENG Fan(The First Affiliated Hospital of Gannan Medical University,Ganzhou 341000,China;不详)
出处
《中国医学创新》
CAS
2023年第26期41-45,共5页
Medical Innovation of China
